.png){kind=icon}
.png){kind=icon}
Return
Acute Lymphoblastic Leukemia, Version 2.2021
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2021.0042.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.
Keywords:
STEM-CELL TRANSPLANTATION
TERM-FOLLOW-UP
CHILDRENS-ONCOLOGY-GROUP
CHRONIC MYELOID-LEUKEMIA
ACUTE LYMPHOCYTIC-LEUKEMIA
MINIMAL RESIDUAL DISEASE
SULFATE LIPOSOME INJECTION
THERAPY IMPROVES SURVIVAL
TYROSINE KINASE INHIBITOR
COMPLETE REMISSION RATE
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations